Search
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat . Sebetralstat is the first and only oral ...
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes.
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSalsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors.
Tyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawnNevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges
Burosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalIt causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life [L2346].
Opaganib
go.drugbank.com/drugs/DB12764InvestigationalOpaganib, also known as ABC294640, is a selective sphingosine kinase-2 (SK2) (https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. This drug has potential anticancer, anti-inflammatory, and antiviral activi...
Hyperforin
go.drugbank.com/drugs/DB01892InvestigationalNutraceuticalHyperforin is a phytochemical generated by the plants of the Hypericum family. One of the most important members of this family, due to its medical properties, is Hypericum perforatum, also known as St John's wort.
Itolizumab
go.drugbank.com/drugs/DB16207InvestigationalItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).